CN103833648A - Crystal compound and application thereof - Google Patents
Crystal compound and application thereof Download PDFInfo
- Publication number
- CN103833648A CN103833648A CN201210491943.XA CN201210491943A CN103833648A CN 103833648 A CN103833648 A CN 103833648A CN 201210491943 A CN201210491943 A CN 201210491943A CN 103833648 A CN103833648 A CN 103833648A
- Authority
- CN
- China
- Prior art keywords
- compound
- anesthetic
- crystal
- application
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a compound crystal and medicinal application thereof, particularly a crystal form of the compound, and application of the crystal form in anesthetization applicable to mammals.
Description
Technical field
The present invention relates to a kind of compound, and the crystalline form of described compound.The invention still further relates to preparation method and the purposes of described compound.
Background technology
Narcotic divides general anesthetic and the large class of local anesthetic two.General anesthetic is divided into inhalation anesthesia medicine and intravenous anesthetic according to administering mode.Local anesthetic is divided into benzoates according to chemical structure, amides and other class.This chapter introduces structure, title, the physico-chemical property of development, classification and the typical medicaments of medicine, has also introduced the structure activity relationship of local anaesthetics.
Anesthesia be the part of body or body under the impact of medicine or other factors, temporarily lose a kind of state of irritant reaction to external world.The medicine that can cause anesthesia is called " narcotic ".Narcotic is divided into general anesthetic (general anesthetics) and the large class of local anesthetic (local anesthetics) two.General anesthetic is divided into again inhalation anesthetic and intravenous anesthetic two classes.General anesthetic acts on nervus centralis, can cause that all consciousness of patient, sensation and reflex activity disappear, and make it be subject to reversible inhibition; Local anesthetic acts on nerve ending or nerve trunk, and the conduction of reversible blocking-up sensory nerve impulsion, makes patient lose pain, is applicable to local minor operation.In the dosage range that acts on permission of this two classes medicine, be all reversible, i.e., after the action time of medicine, anesthesia disappears, and neural function recovers completely, and cell is not shown to any structural infringement.
General anesthetic can be divided into inhalation anesthetic (inhalation anesthetics) and intravenous anesthetic (intravenous anesthetics) according to the mode of administration.The desirable requirement to this type of medicine is: 1, rapid-action, after drug withdrawal, remove rapidly; 2, harmless to health, particularly to the heart, kidney, liver; 3, be easy to control dosage and anesthesia level and time; 4, character is more stable.
Inhalation anesthetic is the inactive volatile liquid of a class chemical property (as ether, fluothane) and gas (as Nitrous Oxide), is mainly hydro carbons, halohydrocarbon, ethers and mineral compound etc. by its structure.The picked-up of main dependence alveolar ventilation and eliminating.Inhale people's narcotic and enter blood flow arrival cerebral tissue through alveolar, when in cerebral tissue
When its dividing potential drop reaches certain level, produce generalized anesthetic state clinically.
Therefore, how to develop efficient anesthesia and the medical compounds that has no side effect is the important topic that researcher need to solve all the time.
Applicant of the present invention studies some compound of the prior art, finds that wherein some compound, particularly crystalline compounds have certain restraining effect to mammiferous neural system.
Summary of the invention
The anesthesiophore compound of a kind of tool, shown in its structural formula following (I):
There is characteristic peak at the following 2 θ angles of described crystal in X ray diffracting spectrum: 6.0,7.4,11.0,12.2,15.6,17.5,19.8,21.6,24.8 and 27.7.
Described compound synthetic can by directly fluoridize method realize.Conventional fluorination reagent has the fluorination reagent such as diethylaminosulfurtrifluoride, pyridine hydrofluoride.In reaction, add bromo-succinimide, N-iodosuccinimide, bromine or iodine etc.
Another aspect of the present invention also relates to pharmaceutical composition, comprising formula (I) compound or their pharmacy acceptable salts of effective dose.
The compounds of this invention can be anaesthetized Mammals effectively.
Accompanying drawing explanation
Fig. 1 is the X-ray powder diffraction pattern of formula I compound crystal of the present invention.
Embodiment
200 grams of modus ponens I compound crude products are at room temperature dissolved in the dichloromethane solution of 50 milliliters, form near saturated solution.On this solution, cover a small amount of hexanaphthene, under room temperature, permeate, slowly volatilization, obtains formula I compound crystal.Fusing point: 211 ~ 212 ℃.
Embodiment 2: pharmacology test
sample preparation method:tested medicine: compound or its crystal are ground and are made into desired concn with distilled water.
test method:the effect of having assessed by the expection anesthesia test in mouse in the body of described medicinal extract is (with reference to the people such as D. J. Sanger, Eur. J. Pharmacol., 313,35-42,1996; With the people such as G. Griebel, Psychopharmacology, 146,205-213,1999).Adopt only multiple groups of male CD1 mouse (body weight 22-26 gram when test) of 5-8.Volume according to 10ml/kg is used test compounds, and according to single equimolecular intraperitoneal dosage, described sample is suspended in 0.25% agar that contains a Tween 80.Two dosage of each approach test.Control animal receives independent carrier.Use Smart System (Panlab, S. L., Spain), with the interval of 5 minutes record in every mouse peritoneum after (ip) administration 30 minutes and oral cavity (po) administration after during 60 minutes in the distance of walking, take cm as unit.Compared with control animal, the inhibition percentage ratio of the travel distance of computing animal (being rejected for first 5 minutes).The results are shown in Table 1.
the impact of table 1 formula I compound on mouse anesthesia
Mouse is through peritoneal administration as shown in Table 1, or after orally administering, formula I compound of the present invention has obvious anesthetic action with Compound Phase ratio of the prior art.
Claims (3)
1. the compound that formula (I) represents, or its pharmacy acceptable salt:
（I），
It is characterized in that, for crystalline form, this crystal belongs to oblique system, there is characteristic peak at the following 2 θ angles of described crystal in X ray diffracting spectrum: 6.0,7.4,11.0,12.2,15.6,17.5,19.8,21.6,24.8 and 27.7.
2. compound as claimed in claim 1, is characterized in that described compound can be used for preparing the purposes of narcotic.
3. a pharmaceutical composition, the compound that it contains claim 1, also contains one or more pharmaceutically acceptable auxiliary agents that are selected from W-Gum, maltodextrin, glucose, lactose, sorbyl alcohol, N.F,USP MANNITOL, sodium starch glycolate, polyvinylpyrrolidone, cyclodextrin derivative, derivatived cellulose, talcum powder, Magnesium Stearate, stearic acid, carnauba wax, Vinlub, beeswax in addition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210491943.XA CN103833648A (en) | 2012-11-28 | 2012-11-28 | Crystal compound and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210491943.XA CN103833648A (en) | 2012-11-28 | 2012-11-28 | Crystal compound and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103833648A true CN103833648A (en) | 2014-06-04 |
Family
ID=50797588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210491943.XA Pending CN103833648A (en) | 2012-11-28 | 2012-11-28 | Crystal compound and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103833648A (en) |
-
2012
- 2012-11-28 CN CN201210491943.XA patent/CN103833648A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104547826B (en) | Galangal rhizome extract treats the medical usage of dysmenorrhoea | |
| CN105287499A (en) | Natural pharmaceutical composition for preventing and treating cardiovascular and cerebrovascular diseases and application of pharmaceutical composition | |
| CN103989695A (en) | Pharmaceutical composition for treating bronchial asthma and application thereof | |
| CN103833648A (en) | Crystal compound and application thereof | |
| CN103833656A (en) | Crystal compound and application thereof | |
| CN103833655A (en) | Crystal compound and application thereof | |
| CN102641240A (en) | Kukoamine B salt injection and preparation method thereof | |
| CN101757016A (en) | Medicine composition for treating flu and preparation method thereof | |
| CN103833740A (en) | Crystal compound and application thereof | |
| CN103585147B (en) | Application of Nitrosporeusines A in preparation of oral ulcer treatment or prevention medicines | |
| CN103585330B (en) | A kind of Chinese medicine composition for cutaneous fungal infection and preparation method thereof | |
| CN103664608B (en) | Crystal compound and application thereof | |
| CN103462951B (en) | Application of scopariusins in preparation of medicine treating or preventing canker sore | |
| CN103664822A (en) | Compound used as anesthetic | |
| CN103599104B (en) | Application of Caesanines D in drug for treating or preventing dental ulcer | |
| CN102872056B (en) | Application of Gypensapogenin A to preparing drugs for treating or preventing canker sores | |
| CN106344555A (en) | Application of Fistulains B in drugs for dental ulcer prevention or treatment | |
| CN107303392A (en) | A kind of polyethylene glycol-naloxone composition and application | |
| CN103356653B (en) | The application of Chukrasone A in preparation treatment or preventing canker sore medicine | |
| CN104510751B (en) | A kind of Chinese medicine monomer composition and use thereof for the treatment of dysmenorrhes | |
| CN103751178B (en) | The application of Trigoxyphin K in increased platelets counts medicine | |
| CN103505464B (en) | The application of Phyllanthoid A in preparation treatment or preventing canker sore medicine | |
| CN103479624B (en) | Application of Racemosins A in preparation of oral ulcer treatment or prevention medicines | |
| CN103720686B (en) | Trigoxyphin K is raising the application in erythrocyte medicine | |
| CN102198133B (en) | Application of 8-difluoro methoxy fluoroquinolone and composition thereof to tuberculosis treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140604 |